Evidence map›Paper›PMID 32993809›Full record

ArticleBiological research2020

MiR-128 suppresses metastatic capacity by targeting metadherin in breast cancer cells.

Danxia Cao, Han Zhu, Qian Zhao, Jianming Huang, Cixiang Zhou, Jianrong He, Yongjun Liang

Open access · goldAbstract read
In one paragraph

Article in Biological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Danxia CaoComprehensive Breast Health Center, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Rui-Jin Er Road, Shanghai, 200025, China.
Han ZhuDepartment of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, No. 2800, Gong-Wei Road, Shanghai, 201399, China.
Qian ZhaoDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Shanghai Jiao Tong University School of Medicine, No. 280, Chong-Qing South Road, Shanghai, 200025, China.
Jianming HuangDepartment of Orthopedics, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, No. 2800, Gong-Wei Road, Shanghai, 201399, China.
Cixiang ZhouDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Shanghai Jiao Tong University School of Medicine, No. 280, Chong-Qing South Road, Shanghai, 200025, China.
Jianrong HeComprehensive Breast Health Center, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Rui-Jin Er Road, Shanghai, 200025, China. hejrong@hotmail.com.
Yongjun LiangCenter for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, No. 2800, Gong-Wei Road, Shanghai, 201399, China. liangyj0214@qq.com.
Pudong Medical Center · CNRuijin Hospital · CNShanghai Jiao Tong University · CN

Funding

National Science Foundation of China 81472463National Science Foundation of China 81772831The Pudong Bureau of Health and Family Planning Grants Pw2016B-18
6 · The paper itself

Abstract

backgroundBreast cancer, the most common cancer in women worldwide, causes the vast majority of cancer-related deaths. Undoubtedly, tumor metastasis and recurrence are responsible for more than 90 percent of these deaths. MicroRNAs are endogenous noncoding RNAs that have been integrated into almost all the physiological and pathological processes, including metastasis. In the present study, the role of miR-128 in breast cancer was investigated.

resultsCompared to the corresponding adjacent normal tissue, the expression of miR-128 was significantly suppressed in human breast cancer specimens. More importantly, its expression level was reversely correlated to histological grade of the cancer. Ectopic expression of miR-128 in the aggressive breast cancer cell line MDA-MB-231 could inhibit cell motility and invasive capacity remarkably. Afterwards, Metadherin (MTDH), also known as AEG-1 (Astrocyte Elevated Gene 1) and Lyric that implicated in various aspects of cancer progression and metastasis, was further identified as a direct target gene of miR-128 and its expression level was up-regulated in clinical samples as expected. Moreover, knockdown of MTDH in MDA-MB-231 cells obviously impaired the migration and invasion capabilities, whereas re-expression of MTDH abrogated the suppressive effect caused by miR-128.

conclusionsOverall, these findings demonstrate that miR-128 could serve as a novel biomarker for breast cancer metastasis and a potent target for treatment in the future.

Indexed as

Breast NeoplasmsMicroRNAsNeoplasm InvasivenessCell Adhesion MoleculesCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMembrane ProteinsNeoplasm Recurrence, LocalRNA-Binding ProteinsCell Adhesion MoleculesMembrane ProteinsMicroRNAsMIRN128 microRNA, humanMTDH protein, humanRNA-Binding ProteinsBreast cancerMetastasismiR-128MTDH

Identifiers

PMID32993809
PMCPMC7526227
OpenAlexW3090503927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.